B- And T-Lymphocyte Attenuator (BTLA) Antibody
195€ (20 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
B- And T-Lymphocyte Attenuator (BTLA) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx006228
tested applications
ELISA, WB
Description
BTLA Antibody is a Rabbit Polyclonal Antibody against BTLA.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | B- And T-Lymphocyte Attenuator (BTLA) |
| Host | Rabbit |
| Reactivity | Mouse, Rat |
| Recommended Dilution | ELISA: 1 µg/ml, WB: 1/1000 - 1/4000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by affinity chromatography. |
| Size 1 | 20 µl |
| Size 2 | 100 µl |
| Size 3 | 2 × 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q7Z6A9 |
| Gene ID | 151888 |
| NCBI Accession | NP_001078826.1 |
| Alias | B- and T-lymphocyte attenuator,BTLA1,CD272, |
| Background | Antibody anti-BTLA |
| Status | RUO |
| Note | Concentration: > 0.2 mg/ml - |
Descripción
B and T Lymphocyte Attenuator (BTLA) is an immunoglobulin superfamily receptor expressed on various immune cells, notably B cells, T cells, macrophages, and dendritic cells. BTLA is a crucial immune checkpoint molecule that modulates immune responses by interacting with its ligand, Herpesvirus entry mediator (HVEM), to maintain immune homeostasis and prevent overactivation that could lead to autoimmune responses. As an immune checkpoint, BTLA is part of a larger family of inhibitory receptors, such as PD-1 and CTLA-4, that regulate immune cell activity to mitigate excessive inflammatory responses. However, BTLA has distinct binding affinities and structural features, which influence its role in modulating immune responses, inflammation, and tolerance. BTLA's interaction with HVEM is unique among immune checkpoint pathways because HVEM also binds several other ligands, including LIGHT (TNFSF14) and lymphotoxin α. This interaction allows for complex regulatory functions, enabling BTLA to provide inhibitory signals that dampen T cell receptor (TCR) and B cell receptor (BCR) signaling. Such regulation is vital in preventing autoimmunity and controlling immune responses in infection, inflammation, and cancer, where immune modulation can prevent tumor growth but also, if dysregulated, may suppress necessary immune responses against cancer cells.
